D. Allen Annis, Cliff C. Cheng, Cheng-Chi Chuang, John D. McCarter, Huw M. Nash, Naim Nazef, Todd Rowe, Robert J.M. Kurzeja and Gerald W. Shipps Jr. Pages 760 - 771 ( 12 )
This manuscript describes the discovery and characterization of inhibitors of the lipid phosphatase SHIP2, an important target for the treatment of Type 2 diabetes, using the Automated Ligand Identification System. ALIS is an affinity selection-mass spectrometry platform for label-free, high throughput screening of mixture-based combinatorial libraries. We detail the mass-encoded synthesis of a library that yielded NGD-61338, a pyrazole-based SHIP2 inhibitor. Quantitative ALIS affinity measurements and inhibition of SHIP2 enzymatic activity indicate that this compound has micromolar binding affinity and inhibitory activity for this target. This inhibitor, which does not contain a phosphatase “warhead,” binds the active site of SHIP2 as determined by ALIS-based competition experiments with the enzymes natural substrate, phosphatidylinositol 3,4,5-triphosphate (PIP3). Structure-activity relationships for NGD-61338 and two other ligand classes discovered by ALIS screening were explored using a combination of combinatorial library synthesis and ALIS-enabled affinity ranking in compound mixtures.
Affinity selection, mass spectrometry, high throughput screening, label-free, SHIP2, ALIS
Aileron Therapeutics, Inc., 840 Memorial Drive, Cambridge, MA 02139, USA.